VIGIL NEUROSCIENCE INC. - COMMON STOCK

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

08 May 2024 06:40:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 15:05:01 By Nasdaq GlobeNewswire

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

17 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

26 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

20 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

13 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

12 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

06 Mar 2024 15:25:47 By Nasdaq GlobeNewswire

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

07 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

03 Jan 2024 15:30:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

22 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

16 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

07 Nov 2023 06:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease

17 Oct 2023 06:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

05 Oct 2023 15:01:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

26 Sep 2023 06:05:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

11 Sep 2023 11:00:00 By Nasdaq GlobeNewswire

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

08 Sep 2023 15:05:38 By Nasdaq GlobeNewswire

Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference

08 Sep 2023 06:05:56 By Nasdaq GlobeNewswire